A Phase 2 interventional study of BAY2433334 and BAY2433334 matching placebo in Acute Myocardial Infarction, sponsored by Bayer. Completed at 160 sites in 14 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2023-04-05.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Myocardial Infarction with a site in United States — 41 open to participants now, 65 under way, 9 of them phase 3. Myocardial Infarction · United States.
Among the 440 studies in Myocardial Infarction with a site in United States, this one is the 60th largest by enrollment of the 301 interventional ones that give a count, is one of 17 that started in 2020, is one of 38 in phase 2, and was the 348th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →41 of the 440 studies in Myocardial Infarction with a site in United States are open now. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 40+
Massachusetts General Hospital · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 18+
Amgen · Sites in United States, Australia, Canada and 1 more country
Ages 50–105
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 61 · Phase 3 76 · Phase 4 25
First in 1988; this study’s year is marked. 17 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,601 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 160 across the 301 interventional studies, 514 across the 136 observational. Of the 337 that completed or were terminated, 132 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
143 of 440 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
Bayer has 5 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
18 of the studies in Myocardial Infarction with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT05371470Mayo ClinicVoice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation | 2026-11 |
| NCT04973397Centre hospitalier de l'Université de Montréal (CHUM)Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study | 2026-12 |
| NCT04521699Mayo ClinicExamination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk. | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 440 studies in Myocardial Infarction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of a dual antiplatelet therapy (acetylsalicylic acid +/- clopidogrel) in patients following a recent heart attack (myocardial infarction) that happens when a blood vessel in the heart suddenly becomes blocked. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Acute myocardial infarction (excluding MI associated with PCI or CABG revascularization procedures) with:
at least one of the following risk factors need to be fulfilled:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BAY2433334
Drug: BAY2433334
Drug: BAY2433334
Other: BAY2433334 matching placebo
Tablet, taken orally once a day.
Tablet, taken orally once a day.
Efficacy - Number of Participants With Composite of CV Death, MI, Stroke and Stent Thrombosis (ST)
CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included. Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction. ST was defined incorporating diagnostic certainty as well as timing: "Definite" ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. "Probable" ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause
Time frame: From baseline up to 52 weeks
Safety - Number of Participants With BARC Bleeding Definition Type 2, 3 and 5
Type 2: any overt, actionable sign of hemorrhage that doesn't fit the criteria for type 3 or 5 but meets at least one of the following criteria: 1) requires nonsurgical, med intervention by a HCP, 2) leads to hospital or rise in level of care, or 3) prompt eval. Type 3a: 1) overt bleed + Hg drop of 3 to \<5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation.
Time frame: From baseline up to 52 weeks
Efficacy - Number of Participants With CV Death
CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included.
Time frame: From baseline up to 52 weeks
Efficacy - Number of Participants With MI
Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. According to MI Universal Definition from 2018 the diagnosis of MI requires combination of: 1. Presence of acute myocardial injury. 2. Evidence of acute myocardial ischemia derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging, or in case of post-mortem pathological findings irrespective of biomarker values.
Time frame: From baseline up to 52 weeks
Efficacy - Number of Participants With Stroke
Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction.
Time frame: From baseline up to 52 weeks
Efficacy - Number of Participants With Stent Thrombosis
ST was defined incorporating diagnostic certainty as well as timing: "Definite" ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. "Probable" ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause
Time frame: From baseline up to 52 weeks
Efficacy - Number of Participants With All Cause Mortality
Time frame: From baseline up to 52 weeks
Safety - Number of Participants With All Bleeding
All bleeding events occurred from first intake of study intervention until 2 days after the last intake of study intervention
Time frame: From baseline up to 52 weeks
Safety - Number of Participants With BARC Bleeding Definition Type 3, 5
Type 3a: 1) overt bleed + Hg drop of 3 to \<5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation.
Time frame: From baseline up to 52 weeks
Safety - Number of Participants With BARC Bleeding Definition Type 1,2,3,5
Type 1: bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a healthcare professional. For BARC bleeding definition 2,3 and 5, please refer to second primary endpoint.
Time frame: From baseline up to 52 weeks
Study was conducted at 157 centers in 14 countries or regions, between 17-Jun-2020 (first participant first visit) and 21-Feb-2022 (last participant last visit)
| Milestone | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo |
|---|---|---|---|---|
| Started | 397 | 401 | 402 | 401 |
| Treated | 395 | 397 | 402 | 399 |
| Completed | 303 | 317 | 309 | 309 |
| Not completed | 94 | 84 | 93 | 92 |
| Withdrew: Subject decision covid-19 pandemic related | 1 | 0 | 1 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 2 | 3 |
| Withdrew: Unspecific | 4 | 2 | 2 | 2 |
| Withdrew: Technical problems | 2 | 2 | 3 | 4 |
| Withdrew: Death | 7 | 2 | 4 | 3 |
| Withdrew: Withdrawal by subject | 7 | 2 | 7 | 4 |
| Withdrew: Physician decision | 4 | 9 | 9 | 5 |
| Withdrew: Subject decision | 34 | 25 | 25 | 26 |
| Withdrew: Adverse event | 35 | 40 | 39 | 44 |
CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included. Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction. ST was defined incorporating diagnostic certainty as well as timing: "Definite" ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. "Probable" ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause
| Participants | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo |
|---|---|---|---|---|
| Efficacy - Number of Participants With Composite of CV Death, MI, Stroke and Stent Thrombosis (ST) | 27 | 24 | 22 | 22 |
Type 2: any overt, actionable sign of hemorrhage that doesn't fit the criteria for type 3 or 5 but meets at least one of the following criteria: 1) requires nonsurgical, med intervention by a HCP, 2) leads to hospital or rise in level of care, or 3) prompt eval. Type 3a: 1) overt bleed + Hg drop of 3 to \<5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation.
| Participants | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo | Pooled Asundexian |
|---|---|---|---|---|---|
| Safety - Number of Participants With BARC Bleeding Definition Type 2, 3 and 5 | 30 | 32 | 42 | 36 | 104 |
CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included.
| Participants | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo |
|---|---|---|---|---|
| Efficacy - Number of Participants With CV Death | 7 | 4 | 5 | 2 |
Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. According to MI Universal Definition from 2018 the diagnosis of MI requires combination of: 1. Presence of acute myocardial injury. 2. Evidence of acute myocardial ischemia derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging, or in case of post-mortem pathological findings irrespective of biomarker values.
| Participants | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo |
|---|---|---|---|---|
| Efficacy - Number of Participants With MI | 18 | 20 | 18 | 17 |
Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction.
| Participants | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo |
|---|---|---|---|---|
| Efficacy - Number of Participants With Stroke | 4 | 3 | 0 | 2 |
ST was defined incorporating diagnostic certainty as well as timing: "Definite" ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. "Probable" ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause
| Participants | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo |
|---|---|---|---|---|
| Efficacy - Number of Participants With Stent Thrombosis | 4 | 5 | 4 | 4 |
| Participants | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo |
|---|---|---|---|---|
| Efficacy - Number of Participants With All Cause Mortality | 10 | 7 | 10 | 7 |
All bleeding events occurred from first intake of study intervention until 2 days after the last intake of study intervention
| Participants | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo |
|---|---|---|---|---|
| Safety - Number of Participants With All Bleeding | 70 | 75 | 82 | 85 |
Type 3a: 1) overt bleed + Hg drop of 3 to \<5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation.
| Participants | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo |
|---|---|---|---|---|
| Safety - Number of Participants With BARC Bleeding Definition Type 3, 5 | 5 | 3 | 3 | 5 |
Type 1: bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a healthcare professional. For BARC bleeding definition 2,3 and 5, please refer to second primary endpoint.
| Participants | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo |
|---|---|---|---|---|
| Safety - Number of Participants With BARC Bleeding Definition Type 1,2,3,5 | 70 | 75 | 82 | 85 |
Collected over After the first administration of study intervention for up to 52 weeks (but not starting after more than 2 days after the last administration). Reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact, for up to 54 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Asundexian 10 mg | 10/397 (2.5%) | 74/395 (18.7%) | 89/395 (22.5%) |
| Asundexian 20 mg | 7/401 (1.7%) | 82/397 (20.7%) | 118/397 (29.7%) |
| Asundexian 50 mg | 10/402 (2.5%) | 67/402 (16.7%) | 94/402 (23.4%) |
| Placebo | 7/401 (1.7%) | 82/399 (20.6%) | 107/399 (26.8%) |
| Event | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo |
|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 9/395 | 9/397 | 10/402 | 8/399 |
| COVID-19Infections and infestations | 1/395 | 1/397 | 7/402 | 5/399 |
| Angina pectorisCardiac disorders | 5/395 | 4/397 | 6/402 | 1/399 |
| Chest painGeneral disorders | 4/395 | 5/397 | 4/402 | 4/399 |
| Cardiac failureCardiac disorders | 3/395 | 4/397 | 2/402 | 5/399 |
| Angina unstableCardiac disorders | 4/395 | 1/397 | 2/402 | 4/399 |
| COVID-19 pneumoniaInfections and infestations | 1/395 | 0/397 | 1/402 | 4/399 |
| Cardiac arrestCardiac disorders | 3/395 | 1/397 | 1/402 | 1/399 |
| AppendicitisInfections and infestations | 3/395 | 0/397 | 0/402 | 0/399 |
| Myocardial infarctionCardiac disorders | 2/395 | 2/397 | 3/402 | 3/399 |
| Event | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo |
|---|---|---|---|---|
| HypertensionVascular disorders | 22/395 | 27/397 | 15/402 | 30/399 |
| Chest painGeneral disorders | 13/395 | 29/397 | 15/402 | 17/399 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 21/395 | 27/397 | 21/402 | 23/399 |
| DiarrhoeaGastrointestinal disorders | 22/395 | 21/397 | 22/402 | 18/399 |
| DizzinessNervous system disorders | 18/395 | 19/397 | 21/402 | 19/399 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 17/395 | 19/397 | 21/402 | 20/399 |
FAS(Full data analysis)
| Age, Categorical(Participants) | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 122 | 123 | 118 | 136 | 499 |
| >=65 years | 275 | 278 | 284 | 265 | 1102 |
| Sex: Female, Male(Participants) | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 93 | 87 | 100 | 90 | 370 |
| Male | 304 | 314 | 302 | 311 | 1231 |
| Race (NIH/OMB)(Participants) | Asundexian 10 mg | Asundexian 20 mg | Asundexian 50 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 0 | 0 | 3 |
| Asian | 53 | 50 | 50 | 50 | 203 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 2 | 1 | 8 |
| White | 334 | 345 | 347 | 339 | 1365 |
| More than one race | 1 | 0 | 2 | 2 | 5 |
| Unknown or Not Reported | 5 | 2 | 1 | 9 | 17 |
Showing the first 100 of 160 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Ran from Jun 2020 to primary completion in Feb 2022, 20 months.
Results were first posted in Apr 2023, 1 year 1 month after primary completion.
Of 45 phase 2 interventional studies under Myocardial Infarction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 42. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Asundexian